Abstract: A method for stabilizing blood glucose levels and reducing the hyperglycemia associated with Type II diabetes. Synthetic chromic tripicolinate is administered either orally or parenterally to a human in need thereof at a dosage of between about 1,000 amd 10,000 micrograms per day.

Abstract: The present invention is particularly directed to the use of a derivative of vinblastine, 3′,4′-anhydrovinblastine (AHVB), which differs from vinblastine in that it possesses a double bond at the 3′,4′ position of the caranthine nucleus rather than the hydroxyl group that is present in the parent structure, as an anti-neoplastic agent in the therapeutic treatment of cancer.

Abstract: In accordance with the present invention there is provided a method of treating a mammal having a solid tumor, the method comprising: a) administering to the mammal an effective amount of 3-ainino-1,2,4-benzotriazine 1,4-dioxide; b) administering to the mammal an effective amount of paclitaxel; and c) administering to the mammal an effective amount of a platinum complex. The method provides unexpected synergistic efficacy. The invention further provides a kit for treatment of a mammalian tumor comprising 3-amino-1,2,-benzotriazine 1,4-dioxide, paclitaxel and a platinum complex.

Abstract: The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering progestin products, either alone or in combination with other agents such as estrogen products.

Abstract: The present invention includes a formulation which comprises an antibacterial substance and an antiulcer substance, wherein at least either of them is formulated into a gastrointestinal mucosa-adherent solid preparation. The formulation of the present invention shows long retention time in the gastrointestinal tract because of adhesion to the gastrointestinal tract mucosa, synergetically enhances the pharmaceutical effects of an antibacterial substance, specially antibiotic against Helicobacter pylori (HP) and an antiulcer substance, with very low doses of active ingredients, particularly the anti-HP antibiotic with low prevalence of side effects. The present agent is useful as an antiulcer agent, showing potent anti-HP activity.

Abstract: A method of treating hyperproliferation diseases in mammals in need of such treatment which method includes administering to said mammal a therapeutically effective amount of a compound of the formula: or a pharmaceutically acceptable salt, hydrate or prodrug thereof, wherein R1, R2, R3, R4, W, X, Y, Z and t are as defined herein.

Abstract: This invention relates to new nucleoside derivatives of formula (I); wherein R1 and R2 are independently selected from hydrogen, elaidoyl, oleoyl, stearoyl, eicosenoyl (cis or trans) and eicosanoyl, with the provisos that R1 and R2 cannot both be hydrogen, oleoyl or stearoyl, R1 cannot be hydrogen when R2 is oleoyl or stearoyl, and R2 cannot be hydrogen when R1 is elaidoyl, oleoyl or stearoyl. Further, the invention relates to the use of the nucleoside derivatives of formula (I) wherein R1 and R2 are independently selected from hydrogen, and C18- and C20-saturated and mono-unsaturated acyl groups, with the provisos that R1 and R2 cannot both be hydrogen, in the manufacture of a pharmaceutical preparation for the treatment of tumours.

Abstract: Disclosed are methods and kits for treating lymphoproliferative diseases in a host including (co)administering to the host pentostatin, at least one alkylating agent and at least one methylated xanthine.

Abstract: The present invention provides pharmaceutical compositions comprising an amount of hydrogenated lupulones or derivatives or analogs thereof, effective to inhibit cancer cell growth, and methods of use thereof.

Abstract: An injectable composition is described having a higher residual effect with reduced detrimental effects such as pain at injection site, swelling, tissue irritancy or necrosis. The composition contains as active principle a tetracycline compound, either as the free base or a salt thereof with a physiologically acceptable acid, complexed with a substantially equimolar amount of a magnesium compound, and is solubilized in a water miscible solvent system comprising glycerol formal in a an amount of about 40 (v/v); with from about 1% to about 20% (v/v) polyethylene glycol and optionally containing a pH modifier in an amount sufficient to maintain a physiologically acceptable pH. In addition, the composition may further comprise a thickener, such as polyvinyl in an amount of about 10% (w/v). The balance of the composition comprises water.

Abstract: The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering progestin products, either alone or in combination with other agents such as estrogen products.

Abstract: This invention is about the identification of the HD-2, a natural chemical substance that was separated and purified from a natural product, Sinsuk, as arsenic hexoxide (As4O6) and about its therapeutic efficacy as an anti-cancer drug and pharmaceutical composition. Arsenic hexoxide (As4O6), a natural chemical substance obtained from Sinsuk after eliminating the toxic property, has a potent anti-cancer efficacy by its direct cytotoxicity on tumor cells and suppresses the formation of new blood vessels of tumor masses, which results in complete cure of malignant cancers.

Abstract: The invention relates to pharmaceutically stable oxaliplatin solution formulations, to the method of use thereof in the treatment of cancer tumors, to processes for the preparation of such formulations, and to a method for stabilizing solutions of oxaliplatin.

Abstract: A pharmaceutical agent comprising an ascorbic acid, a derivative thereof or a salt thereof (ascorbic acids) as an active ingredient, for selectively inducing apoptosis of unnecessary or pathogenic cells to thereby prevent and/or treat diseases caused by said cells; a method for the prophylaxis and/or treatment of diseases caused by unnecessary or pathogenic cells, comprising selectively inducing apoptosis of said cells by the use of ascorbic acids; and use of ascorbic acids for the production of a pharmaceutical agent for selectively inducing apoptosis of unnecessary or pathogenic cells to thereby prevent and/or treat diseases caused by said cells. The ascorbic acids are low toxic and selectively induce apoptosis of unnecessary or pathogenic cells. Therefore, they are useful for the prophylaxis and/or treatment of the diseases caused by said cells.

Abstract: The invention relates to the treatment of a proliferative disease, especially according to certain treatment regimens, with an epothilone, especially with epothilone A and more preferably epothilone B; as well as to the treatment of certain cancers with such an epothilone.

Abstract: A chemotheraputic cancer treatment in which Gö6976 or one of its derivatives is administered to a mammal for the treatment of the cancer. The Gö6976 or its derivative is directed to PKC &agr; activity. Experiments have shown Gö6976 to be effective for the treatment of breast cancer, leukemia, lung cancer, bone cancer and skin cancer. These treatments may be accomplished utilizing Gö6976 or its derivatives alone or in combination with other prior art chemotherapy agents or in combination with radiation therapy. In a preferred embodiment Gö6976 is used for the treatment of cancer as a preventative drug by preventing cancer cell formation.

Abstract: The present invention is directed to a method for treating cancers by administering a pharmaceutically effective amount of a diiodo thyronine analogue having no significant hormonal activity and a vinca alkaloid or biologically active analog thereof. The present invention also features novel pharmaceutical compositions comprising the same.

Abstract: The invention relates to selective induction of cell death by apoptosis and applicability to treatment of leukemias.

Abstract: Indenyl hydroxamic acids, (hydroxy) ureas and urethanes are useful in the treatment of precancerous lesions and neoplasms.

Abstract: The present invention is a composition for preventing, minimizing, or reversing the development or growth of breast cancer. The composition contains a combination of a selective estrogen receptor modulator selected from at least one of raloxifene, droloxifene, toremifene, 4′-iodotamoxifen, and idoxifene and at least one isoflavone selected from genistein, daidzein, biochanin A, formononetin, and their respective naturally occurring glucosides and glucoside conjugates. The present invention also provides a method of preventing, minimizng, or reversing the development or growth of breast cancer in which a selective estrogen receptor modulator selected from at least one of raloxifene, droloxifene, toremifene, 4′-iodotamoxifen, and idoxifene is co-administered with at least one isoflavone selected from genistein, daidzein, biochanin A, formononetin, and their naturally occuring glucosides and glucoside conjugates to a woman having or predisposed to having breast cancer.